Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
Joshua D Campbell,Christina Yau,Reanne Bowlby,Yuexin Liu,Kevin Brennan,Huihui Fan,Alison M Taylor,Chen Wang,Vonn Walter,Rehan Akbani,Lauren Averett Byers,Chad J Creighton,Cristian Coarfa,Juliann Shih,Andrew D Cherniack,Olivier Gevaert,Marcos Prunello,Hui Shen,Pavana Anur,Jianhong Chen,Hui Cheng,D Neil Hayes,Susan Bullman,Chandra Sekhar Pedamallu,Akinyemi I Ojesina,Sara Sadeghi,Karen L Mungall,A Gordon Robertson,Christopher Benz,Andre Schultz,Rupa S Kanchi,Carl M Gay,Apurva Hegde,Lixia Diao,Jing Wang,Wencai Ma,Pavel Sumazin,Hua-Sheng Chiu,Ting-Wen Chen,Preethi Gunaratne,Larry Donehower,Janet S Rader,Rosemary Zuna,Hikmat Al-Ahmadie,Alexander J Lazar,Elsa R Flores,Kenneth Y Tsai,Jane H Zhou,Anil K Rustgi,Esther Drill,Ronglei Shen,Christopher K Wong,Cancer Genome Atlas Research Network,Joshua M Stuart,Peter W Laird,Katherine A Hoadley,John N Weinstein,Myron Peto,Curtis R Pickering,Zhong Chen,Carter Van Waes
DOI: https://doi.org/10.1016/j.celrep.2018.03.063
2018-04-03
Abstract:This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with smoking and/or human papillomavirus (HPV). SCCs harbor 3q, 5p, and other recurrent chromosomal copy-number alterations (CNAs), DNA mutations, and/or aberrant methylation of genes and microRNAs, which are correlated with the expression of multi-gene programs linked to squamous cell stemness, epithelial-to-mesenchymal differentiation, growth, genomic integrity, oxidative damage, death, and inflammation. Low-CNA SCCs tended to be HPV(+) and display hypermethylation with repression of TET1 demethylase and FANCF, previously linked to predisposition to SCC, or harbor mutations affecting CASP8, RAS-MAPK pathways, chromatin modifiers, and immunoregulatory molecules. We uncovered hypomethylation of the alternative promoter that drives expression of the ΔNp63 oncogene and embedded miR944. Co-expression of immune checkpoint, T-regulatory, and Myeloid suppressor cells signatures may explain reduced efficacy of immune therapy. These findings support possibilities for molecular classification and therapeutic approaches.